HC Wainwright Reaffirms “Buy” Rating for TransCode Therapeutics (NASDAQ:RNAZ)

HC Wainwright restated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ) in a research note published on Thursday, Benzinga reports. They currently have a $3.00 price target on the stock.

TransCode Therapeutics Price Performance

Shares of NASDAQ RNAZ opened at $0.59 on Thursday. TransCode Therapeutics has a twelve month low of $0.22 and a twelve month high of $19.42. The firm has a fifty day simple moving average of $0.44 and a 200 day simple moving average of $0.70.

TransCode Therapeutics (NASDAQ:RNAZ) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.16). As a group, research analysts anticipate that TransCode Therapeutics will post -2.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC acquired a new position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned about 0.84% of TransCode Therapeutics at the end of the most recent reporting period.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.